Kurs & Likviditet
|2019-09-24||Extra Bolagsstämma 2019|
|2019-06-10||Extra Bolagsstämma 2019|
|2019-06-07||Ordinarie utdelning FOLLI 0.00 SEK|
|2018-06-04||Extra Bolagsstämma 2018|
|2018-05-31||Ordinarie utdelning FOLLI 0.00 SEK|
|2017-09-27||Extra Bolagsstämma 2017|
|2017-04-27||Ordinarie utdelning FOLLI 0.00 SEK|
|2016-06-14||Ordinarie utdelning FOLLI 0.00 SEK|
|2016-04-01||Extra Bolagsstämma 2016|
|2015-02-26||Ordinarie utdelning FOLLI 0.00 SEK|
What is your background and what have you done before joining Follicum?
I have more than 35 years of experience in marketing and licensing within the global pharmaceutical industry. Today, I hold the position as Head of Nordic at Tesaro, an American biotech company in oncology, recently acquired by GSK. I have extensive experience from senior positions at Astellas Pharma Norden/Baltic (CEO), Novo Nordisk, Pharmacia Corporation and Ferring International. I am also a Board Member of Gedea Biotech AB as well as Nordic Rebalance a/s and I own MS Persson Consulting AB where I support Companies within Strategy, Marketing and Sales.
Why did you join Follicum as a Board Member?
It is an interesting company, with 2 very exciting drug candidates, both in areas where there is a high unmet medical need. There are very few alternatives to treat hair loss today and it seems as Follicum has one of the few clinical candidates with a clear promise of delivering a safe, effective and convenient hair growth product. The recent patent application for the topical formulation strengthens the case further. Follicum is starting a POC trial this year that will read out already 2020 and this will be extremely interesting to follow! I am very excited that Follicum is pursuing diabetic complications with their novel peptides and that they already have identified a drug candidate. This is something that Big Pharma is looking for!
What expertise will you bring to the Follicum Board?
My experience is mainly on the commercial side. I have broad experience in how to launch products successfully and how to build competitive organisations. I am interested in the life science area in general, especially indications where there is a high unmet medical need, or less effective/safe treatment alternatives today where Follicum's two indication areas hair growth and diabetic complications fits very nicely. I have a diploma in Management and Corporate Governance from EFL, Lund 2017, and have board experience from small start-up companies within Life Science, so I hope to bring that experience to the table in Follicum.
For further information, please contact:
Jan Alenfall - CEO, Follicum AB
Telephone: +46 (0)46 - 19 21 97
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com